Foghorn Therapeutics Inc. Stock Price, News & Analysis

Foghorn Therapeutics (Nasdaq: FHTX) announced presentation and investor event updates on its targeted protein degrader programs. A Keynote Plenary presentation on the Selective ARID1B degrader will be delivered on Oct 29, 2025 at 3:45 p.m. EDT at the 8th Annual TPD and Induced Proximity Summit in Boston.

Foghorn will host a virtual investor event on Oct 30, 2025 at 12 p.m. EDT to review pipeline updates for the Selective ARID1B, Selective CBP, and Selective EP300 degrader programs, including progress toward IND‑enabling studies. The presentation and replay will be available on the company website under Science and Events & Presentations.

Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, has announced its participation in three upcoming investor conferences in September 2025.

The company will attend Citi's 2025 Biopharma Back to School Summit on September 3, the 2025 Wells Fargo Healthcare Conference on September 4, and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Management will conduct one-on-one meetings at all three events.

Foghorn's Gene Traffic Control® platform focuses initially on oncology applications, aiming to develop treatments for a broad spectrum of diseases.

Harbinger Health announced the appointment of Ajit Singh, Ph.D. as its new CEO and CEO-Partner of Flagship Pioneering. Singh, who has served on Harbinger's board since 2024, brings extensive diagnostics industry experience, particularly from his tenure at Siemens and leadership in oncology diagnostics companies.

Current CEO Stephen Hahn, M.D. will transition to CEO Emeritus and Special Advisor while maintaining his position on the Board of Directors. The leadership change comes as Harbinger advances its platform for early cancer detection using blood-based tests that analyze proprietary methylation patterns of cell-free ctDNA.

The company recently presented data showing promising results in detecting multiple high-incidence, high-mortality cancers related to obesity, along with platform innovations to enhance cancer signal detection.

Foghorn Therapeutics (Nasdaq: FHTX) released its Q2 2025 financial and corporate update, highlighting significant progress across its clinical pipeline. The company's lead program, FHD-909, a first-in-class SMARCA2 selective inhibitor targeting NSCLC, is progressing well in Phase 1 trials. Preclinical data showed synergistic benefits when combined with pembrolizumab and KRAS inhibitors.

The company reported strong financial position with $198.7 million in cash and equivalents, extending runway into 2028. Q2 2025 saw collaboration revenue of $7.6 million and a reduced net loss of $17.9 million compared to $23.0 million in Q2 2024. Multiple pipeline developments are expected, including the advancement of their Selective CBP degrader program targeting IND in 2026, and updates on EP300 and ARID1B degrader programs in Q4 2025.

Flagship Pioneering has unveiled Terrana Biosciences, a new agricultural technology company developing RNA-based solutions for crop enhancement and protection. The company emerges with an initial $50 million commitment from Flagship Pioneering after four years of platform development.

Terrana's proprietary RNA technology platform enables the development of targeted products that can work throughout a plant's lifecycle, creating solutions that adapt to variable climate conditions. The company has already demonstrated proof of concept in tomatoes, corn, and soy, and generated a pipeline of over 15 potential products in specialty and row crops.

The company's platform leverages AI and computational models to assemble a vast RNA library and design system for creating novel functional crop traits. Their solutions aim to help farmers combat diseases and pests, adapt to climate conditions, and maintain soil health, while offering advantages over conventional approaches in terms of timing flexibility and environmental impact.

Foghorn Therapeutics (NASDAQ: FHTX) has reported its Q1 2025 financial results and corporate updates. The company's lead candidate, FHD-909, is advancing in Phase 1 dose escalation trials for SMARCA4-mutated cancers, primarily targeting non-small cell lung cancer. Recent data presented at AACR demonstrated synergistic activity with pembrolizumab and KRAS inhibitors. The company is progressing with multiple pipeline programs, including a Selective CBP degrader (targeting IND in 2026), EP300 degrader, and ARID1B degrader programs, with updates expected in H2 2025.

Financially, Foghorn reported Q1 2025 collaboration revenue of $6.0 million, up from $5.1 million in Q1 2024. Net loss improved to $18.8 million compared to $25.0 million in the prior year. The company maintains a strong balance sheet with $220.6 million in cash, cash equivalents, and marketable securities as of March 31, 2025, providing runway into 2027.

Cellarity has appointed Ted Myles as its new Chief Executive Officer and CEO-Partner at Flagship Pioneering. Myles brings extensive biopharma leadership experience, previously serving as CFO and COO of Scholar Rock where he raised over $1 billion and led the company through a successful Phase 3 study. His prior roles include executive positions at AMAG Pharmaceuticals, Ocata Therapeutics, and PrimeraDx.

The appointment comes as Cellarity prepares for its first clinical study in 2025. The company leverages an AI/ML-enabled platform for drug discovery, focusing on understanding dysregulated pathways in diseased human cells. Their lead program, CLY-124, is a potential first-in-class small molecule for sickle cell disease treatment, targeting fetal hemoglobin induction through a novel mechanism, with clinical development expected to begin in mid-2025.

Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company focused on developing medicines that correct abnormal gene expression, announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO Adrian Gottschalk will present in a fireside chat on May 7 at 9:30 a.m. EST and participate in one-on-one meetings throughout the day. The company's Gene Traffic Control® platform primarily targets oncology applications and aims to develop treatments for a broad spectrum of diseases.

Foghorn Therapeutics (FHTX) has appointed two new members to its Board of Directors: Neil Gallagher, M.D., Ph.D., and Stuart Duty. The clinical-stage biotechnology company, which focuses on developing medicines that correct abnormal gene expression, will benefit from their extensive biotechnology industry experience. Both new directors expressed enthusiasm about Foghorn's potential in developing selective therapies for various cancers and its capabilities in selective protein degradation.